Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $6.48, moving -1.52% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.22% for the day. Meanwhile, the Dow experienced a drop of 0.03%, and the technology-dominated Nasdaq saw a decrease of 0.33%.
The the stock of biotechnology company has fallen by 39.47% in the past month, lagging the Medical sector's loss of 0.63% and the S&P 500's loss of 7.48%.
Market participants will be closely following the financial results of Recursion Pharmaceuticals in its upcoming release. The company's upcoming EPS is projected at -$0.44, signifying a 12.82% drop compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $20.15 million, reflecting a 46.12% rise from the equivalent quarter last year.
RXRX's full-year Zacks Consensus Estimates are calling for earnings of -$1.41 per share and revenue of $88.55 million. These results would represent year-over-year changes of +16.57% and +50.5%, respectively.
Any recent changes to analyst estimates for Recursion Pharmaceuticals should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.18% higher. At present, Recursion Pharmaceuticals boasts a Zacks Rank of #3 (Hold).
The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 85, putting it in the top 34% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>Recursion Pharmaceuticals, Inc. (RXRX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
